BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BerGenBio AS Completes $9 Million Series A Financing for First in Class Oncology Therapeutics


1/9/2012 7:28:02 AM

BERGEN, Norway--(BUSINESS WIRE)-- BerGenBio AS, an emerging oncology biopharma company, today announced it has completed an $8.8 million Series A financing round. The financing will be used primarily to take lead compound BGB324 into clinical trials and to develop a companion diagnostic. Lead investors are Sarsia Seed AS and Investinor AS.

BerGenBio CEO Richard Godfrey commented: “This significant new funding from both existing investors and now from Investinor, we believe supports our decision to focus on developing BGB324, our first-in-class Axl kinase inhibitor drug, rapidly towards clinical trials. BGB324 recently attracted a great deal of attention at the annual American Society for Hematology conference in San Diego, where data were presented data showing the compound inhibited tumour development in preclinical Acute Myelogenous Leukemia (AML) models. Furthermore we have shown that inhibition of Axl blocks the epithelial-mesenchymal transistion (EMT) in cancer cells and has the potential to delay or prevent metastasis, overcome and even reverse acquired resistance to chemotherapy and possibly prevent cancer recurrence. We now look forward to completing the preclinical work and taking BGB324, into the clinic by the end of 2012, as well as developing an AXL biomarker for theranostic use.”

Sveinung Hole, CEO of Sarsia Seed, a leading provider of seed capital in Norway, added that he was delighted to increase its investment in BerGenBio: “We regard BerGenBio as one of the most promising companies in our life sciences portfolio and are particularly impressed by the way in which the management is driving the preclinical development programme for BGB324 forward and meeting all preset milestones. We consider that the high quality of research and development at BerGenBio is the critical factor that has led to this significant funding in today’s challenging financial climate. We see BerGenBio’s success as “seeding” a long awaited biotech cluster here in Bergen.”

Anne-Tove Kongness, Investment Director at Investinor, a Norwegian-government-owned venture investment company commented: “We invest in Norwegian companies that have the potential to truly compete on an international basis. We believe that BerGenBio has the ability to do this by taking what is already world-class oncology research in Bergen and translating it into first-in-class therapeutics.”

Notes to editors

BerGenBio AS is an oncology-based biopharmaceutical company located in Bergen, Norway focused on pursuing novel therapeutic treatments for cancer and supporting the screening and identification of a wide array of potential targets in collaboration with other pharmaceutical companies. BerGenBio has a proprietary platform technology called CellSelect™, which uses information from RNAi screening studies to identify novel drug targets involved in disease.The company has a deep understanding of cancer biology and in particular the tumor micro-environment, EMT and mechanisms of drug resistance. BGB324, a first-in-class inhibitor of AXL kinase, is the first of a planned pipeline of oncology therapeutics planned for clinical development through to phase II in partnership with industry leaders. The company’s investors include Investinor, Sarsia Seed, Sarsia Development, Norsk Innovasjonskapital, Birk Venture, Meteva and employees. www.bergenbio.com

Sarsia Seed AS is a Norwegian Seed Capital Fund, which invests in Norwegian early phase technology companies within the energy/cleantech and biotechnology/life science sectors. The fund has a total capital of 333.5 million NOK (approx, 40 mEUR/50 mUSD) and is managed by Sarsia Seed Management AS. The management company advises the Fund board regarding investment decisions. The Fund’s duration is expected to be 12 (+3) years. www.sarsiaseed.com

Investinor AS invests in Norwegian-based, high potential companies that are internationally oriented and in phases ranging from early growth to expansion. The company has BNOK 2.2 under management. Investinor AS has a co-investment strategy and can take up to 49% equity ownership of a portfolio company. Investinor is fully owned by Innovation Norway, which in turn is owned by the Norwegian Ministry of Trade and Industry. www.investinor.no

Contact:

BerGenBio AS

Richard Godfrey, CEO

Richard.Godfrey@bergenbio.com

Tel +47 917 86 304

or

Media:

Richard Hayhurst, Schwartz MSL

rhayhurst@schwartzmsl.com

Tel +44 7950 878218



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES